Evidence map›Paper›PMID 31452067›Full record

ReviewDrugs & aging2019

Practical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause.

Risa Kagan, Susan Kellogg-Spadt, Sharon J Parish

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drugs & aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Randomized clinical trial of vaginal microbiota in menopausal genitourinary syndrome using radiofrequency and topical estriol.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2025
    Trial
  3. Article
  4. Toxicants in sexual health products: highlighting a critical research gap.Journal of exposure science & environmental epidemiology · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Review
  12. Multifaceted Impact of COHealthcare (Basel, Switzerland) · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Risa KaganDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, Affiliated with Sutter East Bay Medical Foundation, Sutter East Bay Medical Group, 2500 Milvia Street, Berkeley, CA, 94704, USA. kaganr@sutterhealth.org.ORCID http://orcid.org/0000-0002-6826-0787
Susan Kellogg-SpadtDrexel University College of Medicine, Philadelphia, PA, USA.
Sharon J ParishWeill Cornell Medical College, New York, NY, USA.
Bryn Mawr College · USCornell University · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genitourinary syndrome of menopause is a condition comprising the atrophic symptoms and signs women may experience in the vulvovaginal and bladder-urethral areas as a result of the loss of sex steroids that occurs with menopause. It is a progressive condition that does not resolve without treatment and can adversely affect a woman's quality of life. For a variety of reasons, many symptomatic women do not seek treatment and, of those who do, many are unhappy with their options. Additionally, many healthcare providers do not actively screen their menopausal patients for the symptoms of genitourinary syndrome of menopause. In this review, we discuss the clinical presentation of genitourinary syndrome of menopause as well as the treatment guidelines recommended by the major societies engaged in women's health. This is followed by a review of available treatment options that includes both hormonal and non-hormonal therapies. We discuss both the systemic and vaginal estrogen products that have been available for decades and remain important treatment options for patients; however, a major intent of the review is to provide information on the newer, non-estrogen pharmacologic treatment options, in particular oral ospemifene and vaginal prasterone. A discussion of adjunctive therapies such as moisturizers, lubricants, physical therapy/dilators, hyaluronic acid, and laser therapy is included. We also address some of the available data on both the patient and healthcare providers perspectives on treatment, including cost, and touch briefly on the topic of treating women with a history of, or at high risk for, breast cancer.

Indexed as

Estrogen Replacement TherapyFemaleFemale Urogenital DiseasesHumansMenopauseQuality of LifeRandomized Controlled Trials as TopicSyndromeWomen's Health

Identifiers

PMID31452067
PMCPMC6764929
OpenAlexW2971019482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.